Search

Displaying results 1751 - 1760 of 4236 in total
  1. Drug

    Arbekacin

    go.drugbank.com/drugs/DB06696
    Investigational

    Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant _Staphylococcus aureus_ (MRSA).

  2. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection.

  3. Drug

    Gadobenic acid

    go.drugbank.com/drugs/DB00743
    ApprovedInvestigational

    [A263166] As gadobenate dimeglumine is specifically taken up by hepatocytes and excreted through the biliary system, it is a useful contrast agent for liver MRI.

  4. Drug

    Ritlecitinib

    go.drugbank.com/drugs/DB14924
    ApprovedInvestigational

    It has been suggested that the dual activity of ritlecitinib toward JAK3 and the TEC kinase family block cytokine signaling as well as the cytolytic activity of T cells, both implicated in the pathogenesis

  5. Drug

    Vutrisiran

    go.drugbank.com/drugs/DB16699
    ApprovedInvestigational

    [L34490,L42065] Vutrisiran is commercially available as a conjugate of N-acetylgalactosamine (GalNAc), a residue that enables the delivery of siRNA to hepatocytes.

  6. Drug

    Malathion

    go.drugbank.com/drugs/DB00772
    Approved

    Malathion is a parasympathomimetic organophosphate compound that is used as an insecticide for the treatment of head lice.

  7. Drug

    Tubocurarine

    go.drugbank.com/drugs/DB01199
    ApprovedWithdrawn

    [A216048] Safer and more pharmacokinetically favorable non-depolarizing neuromuscular blockers, such as [rocuronium], have largely replaced the use of tubocurarine in the clinical setting.[A216048]

  8. Drug

    RPI-78M

    go.drugbank.com/drugs/DB05740
    Experimental

    Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).

  9. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

  10. Drug

    Belantamab mafodotin

    go.drugbank.com/drugs/DB15719
    ApprovedInvestigationalWithdrawn

    A216756] Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma;[L15326] however, its manufacturer began the process for withdrawal of the US